Evaxion's AI-powered Vaccine Discovery Platform 'Eden' Receives Validation

Evaxion's AI platform Eden uses machine learning techniques to simulate the human immune system and predict the effective antigens for a given pathogen.  The platform is fully AI-driven and designed to identify vaccine candidates faster and cheaper than current state-of-the-art methods.

Denmark-based Evaxion Biotech has received validation for its AI-powered vaccine discovery platform, called Eden. This platform is designed to identify novel and protective antigens for bacterial diseases.

The validation process relied on the company's preclinical data that showed a correlation between the AI predictions and the in vivo protection against various bacterial pathogens.

Evaxion's AI platform Eden uses machine learning techniques to simulate the human immune system and predict the effective antigens for a given pathogen. The platform is fully AI-driven and designed to identify vaccine candidates faster and cheaper than current state-of-the-art methods.

Andreas Holm Mattsson, founder and chief AI officer, Evaxion, said, "Evaxion thus becomes the first organization to identify and design bacterial vaccine antigens solely through computational methods, outcompeting reverse vaccinology approaches. We believe this heralds a paradigm shift in vaccine discovery."

Founded in 2008, the Denmark-based biotech company specialises in developing AI-powered immunotherapies. The company utilises its proprietary and scalable technologies, harnessing the capabilities of AI, to decode the complexities of the human immune system. This enables the development of novel immunotherapies for cancer, bacterial infections, and viral diseases, that can save lives and improve the quality of life of patients

With its AI platform Eden, Evaxion aims to take a novel approach to vaccine development to combat the rising global issue of antibiotic resistance.